Literature DB >> 1692300

The autoimmune response of different mouse strains to T-cell epitopes of the human acetylcholine receptor alpha subunit.

S Brocke1, M Dayan, J Rothbard, S Fuchs, E Mozes.   

Abstract

The specific recognition of the acetylcholine receptor and its alpha-subunit by T cells derived from patients with myasthenia gravis or mice with experimental autoimmune myasthenia gravis raises the question of the role of autoreactive T cells in the myasthenic process. Sequences of the acetylcholine receptor alpha-subunit previously shown to be immunogenic in myasthenic patients were tested for their immunogenicity in various inbred mouse strains. High, intermediate and low T-cell proliferative responses could be observed to peptides representing sequences 195-212 and 259-271 of the human acetylcholine receptor alpha-subunit. Following immunization with the Torpedo acetylcholine receptor, lymphocytes of SJL mice proliferated efficiently to p 195-212 but not to p259-271. On the other hand, lymph node cells of BALB/c mice responded well to p259-271 but not to p195-212. Thus, the influence of the genetic make-up of the examined mice on the immune response to the two peptides could be clearly demonstrated by the existence of strain-dependent immunodominant and cryptic regions on the autoantigen. The differences between the strains were less pronounced when antibody responses were measured to these two T-cell epitopes, although a partial correlation with the proliferative responses could be observed. It can be concluded that epitopes specifically recognized by T lymphocytes of patients with myasthenia gravis also represent specific T-cell epitopes in the autoreactivity to the acetylcholine receptor in mice and that immune responsiveness to these peptides is influenced by the genetic make-up of the responding mouse strains.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692300      PMCID: PMC1385618     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  T lymphocyte recognition of acetylcholine receptor: localization of the full T cell recognition profile on the extracellular part of the alpha chain of Torpedo californica acetylcholine receptor.

Authors:  T Yokoi; B Mulac-Jericević; J Kurisaki; M Z Atassi
Journal:  Eur J Immunol       Date:  1987-12       Impact factor: 5.532

2.  T cell hybridomas reactive with the acetylcholine receptor and its subunits.

Authors:  J A Tami; O E Urso; K A Krolick
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

3.  Immunochemical studies on acetylcholine receptor from Torpedo californica.

Authors:  A Aharonov; R Tarrab-Hazdai; I Silman; S Fuchs
Journal:  Immunochemistry       Date:  1977-02

4.  Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor.

Authors:  S Tzartos; L Langeberg; S Hochschwender; J Lindstrom
Journal:  FEBS Lett       Date:  1983-07-11       Impact factor: 4.124

5.  Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor.

Authors:  M Noda; Y Furutani; H Takahashi; M Toyosato; T Tanabe; S Shimizu; S Kikyotani; T Kayano; T Hirose; S Inayama
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

6.  Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits.

Authors:  S J Tzartos; J M Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

7.  T cell epitopes in experimental autoimmune myasthenia gravis of the rat: strain-specific epitopes and cross-reaction between two distinct segments of the alpha chain of the nicotinic acetylcholine receptor (Torpedo californica).

Authors:  Y Zhang; T Barkas; M Juillerat; B Schwendimann; H Wekerle
Journal:  Eur J Immunol       Date:  1988-04       Impact factor: 5.532

8.  Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies.

Authors:  S J Tzartos; M E Seybold; J M Lindstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1982-01       Impact factor: 11.205

9.  T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis.

Authors:  S S Zamvil; D J Mitchell; A C Moore; K Kitamura; L Steinman; J B Rothbard
Journal:  Nature       Date:  1986 Nov 20-26       Impact factor: 49.962

10.  A sequence pattern common to T cell epitopes.

Authors:  J B Rothbard; W R Taylor
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598

View more
  15 in total

1.  Down-regulation of myasthenogenic T cell responses by a dual altered peptide ligand via CD4+CD25+-regulated events leading to apoptosis.

Authors:  Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-26       Impact factor: 11.205

2.  A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.

Authors:  Badiga Venkata Aruna; Hava Ben-David; Michael Sela; Edna Mozes
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

Review 3.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 4.  Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease.

Authors:  William F Pendergraft; Barrak M Pressler; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  J Mol Med (Berl)       Date:  2004-12-11       Impact factor: 4.599

5.  Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.

Authors:  Ronit Mazor; Devorah Crown; Selamawit Addissie; Youjin Jang; Gilad Kaplan; Ira Pastan
Journal:  Cell Mol Immunol       Date:  2015-10-19       Impact factor: 11.530

6.  Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice.

Authors:  M Paas-Rozner; M Dayan; Y Paas; J P Changeux; I Wirguin; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

7.  Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs.

Authors:  Y Katz-Levy; S L Kirshner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

8.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

9.  Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes.

Authors:  A Faber-Elmann; M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand.

Authors:  Hava Ben-David; Amir Sharabi; Molly Dayan; Michael Sela; Edna Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.